CT Screening Reduces Lung Cancer Mortality in High-Risk Men and Women

The uptake of lung cancer screening is low, despite the fact that the National Lung Screening Trial (NLST) found a 20% relative reduction in lung cancer mortality for high-risk individuals (current and former heavy smokers) with annual screening using low-dose computed tomography (CT). Interestingly, a post-hoc analysis of this trial suggested a differential benefit of […]

Read More

First-Line Atezolizumab Plus Chemotherapy Prolongs Survival in SCLC

For more than 20 years, the standard of care for newly diagnosed patients with extensive stage small cell lung cancer (SCLC) has been the combination of platinum (cisplatin or carboplatin) and etoposide chemotherapy. Although this combination yields high response rates (60% to 65%), outcomes remain poor, with a median survival of around 10 months. In […]

Read More

First-Line Brigatinib Superior to Crizotinib in ALK-Positive NSCLC

Patients with metastatic non-small cell lung cancer (NSCLC) with molecular alterations in the ALK gene are sensitive to treatment with ALK-targeted tyrosine kinase inhibitors (TKIs). For many years, the ALK inhibitor crizotinib was the standard of care in this setting, though it has recently been replaced by the second-generation ALK inhibitor alectinib, on the basis […]

Read More

Durvalumab Prolongs Overall Survival in Unresectable Stage III NSCLC

The 19th World Conference on Lung Cancer (WCLC) was recently held from September 23 to 26 in Toronto, Ontario, Canada. Important results were presented from several studies that have the potential to impact clinical practice. Over the next few weeks, prIME LINES will highlight some key results, beginning with highly anticipated overall survival (OS) data […]

Read More

Anti-BCMA CAR T Cells Therapy Active in Pretreated Multiple Myeloma

Despite significant advances in the treatment of multiple myeloma (MM) and substantial improvement in survival in the past decade, it remains an incurable disease. Patients with relapsed MM who are double refractory to proteasome inhibitors and immunomodulatory drugs (IMiDs), or who have relapsed after ≥3 prior therapies, have a median survival of 8 months. Chimeric […]

Read More

Combo Improves Outcomes in Waldenström Macroglobulinemia

Adding Ibrutinib to Rituximab Improves PFS Over Rituximab Alone Waldenström macroglobulinemia (WM) is an uncommon plasma-cell disorder, characterized by overproduction of serum immunoglobulin M (IgM). While there is no standard of care for WM, the anti-CD20 monoclonal antibody rituximab is a common treatment for both treatment-naïve and previously treated patients. Furthermore, based on results from […]

Read More

RET Inhibitor LOXO-292 Shows Promise in Phase I Trial

Alterations in the oncogene RET occur in several solid tumors, including non-small cell lung cancer (NSCLC), thyroid cancer, and pancreatic cancer. Unfortunately, previous attempts to target these alterations with multikinase inhibitors have failed. LOXO-292 is a potent and highly selective RET inhibitor that has demonstrated high activity against RET-altered tumors in both in vitro and […]

Read More

Low-Dose Maintenance Chemo for High-Risk Rhabdomyosarcoma

For the vast majority of patients with rhabdomyosarcoma, a rare soft-tissue sarcoma occurring more commonly in children, standard therapy comprising of surgery, radiation, and high-dose chemotherapy leads to long-term survival and potential cure. However, for high-risk patients or those who progress on first-line therapy, outcomes are poor. With a cure rate of only 20% to […]

Read More

Pembrolizumab and Chemo Combo New Option for Squamous NSCLC

In recent years immunotherapy with PD-1 inhibitors has become the standard of care for first-line treatment of patients with nonsquamous non-small cell lung cancer (nonsq NSCLC) in the absence of targetable driver mutations. For patients with PD-L1 expression >50%, pembrolizumab monotherapy is an approved treatment option for both nonsq and squamous (sq) NSCLC. Based on […]

Read More

Adjuvant mFOLFIRINOX, New Standard of Care for Resectable Pancreatic Cancer

The most common treatment approach for patients with resectable pancreatic cancer is surgery, followed by six cycles of adjuvant chemotherapy with gemcitabine or, more recently, with gemcitabine/capecitabine in combination. Unfortunately, the majority of patients relapse within two years, highlighting a need for improved treatment options for early stage pancreatic cancer. At the 2018 American Society […]

Read More